Recent KRYS News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/03/2026 08:34:01 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/03/2026 08:32:43 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/03/2026 08:31:33 PM
- Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 11:26:21 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 11:24:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:33:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 05:56:22 PM
- Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference • GlobeNewswire Inc. • 02/24/2026 01:00:00 PM
- Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates • IH Market News • 02/17/2026 03:49:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 12:06:52 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/17/2026 12:05:57 PM
- Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2026 12:08:54 AM
- Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2026 09:04:18 PM
- Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 02/09/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 12:50:51 PM
- Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/11/2026 06:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 09:35:06 PM
- Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis • GlobeNewswire Inc. • 01/08/2026 09:01:00 PM
- Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/05/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 09:51:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/04/2025 09:38:34 PM
